Renascience

Renascience Debt / Assets

Debt-to-Assets Ratio of Renascience (4889.T) as of Nov 19, 2026.

Debt / Assets

0.00

Last updated:

Debt-to-Assets Ratio of Renascience is 2025 0.00 . Debt-to-Assets Ratio of Renascience was 2024 0.17 . It decreases by % lower compared to the previous year.

The Renascience Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2020
0.38 JPY
Jan 1, 2021
0.45 JPY
Jan 1, 2022
0.08 JPY
Jan 1, 2023
0.14 JPY
Jan 1, 2024
0.17 JPY
Jan 1, 2025
0.00 JPY
The Renascience Debt / Assets history
YEARDebt / AssetsYoY
0.00-100.00%
0.17+25.26%
0.14+66.55%
0.08-81.68%
0.45+18.84%
0.38—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Renascience

All Key Metrics — Renascience